Literature DB >> 23811610

Field seasonal influenza vaccine effectiveness: evaluation of the screening method using different sources of data during the 2010/2011 French influenza season.

Alessandra Falchi1, Cecile Souty, Marie-Lise Grisoni, Anne Mosnier, Thomas Hanslik, Isabelle Daviaud, Laurent Varesi, Solen Kerneis, Fabrice Carrat, Thierry Blanchon.   

Abstract

Thanks to the screening method, we estimated among target groups the 2010/2011 field vaccine effectiveness (FVE) against laboratory confirmed influenza cases seen in general practice. We also compared the values of FVE estimations obtained by using three sources of the population vaccination coverage (VC) based on three different methodologies: (1) administrative data from the main social security scheme (Caisse Nationale d'Assurance Maladie des Travailleurs Salariés--CNAMTS) covering about 85% of the French population, (2) a cross-sectional national telephone survey in the general population, and (3) a declarative survey in the population seen in a one-day general practitioner (GP) consultations. The FVE estimates among target groups were stratified by age (< 65 y old with reported chronic illness; ≥65 y old and overall). Using the VC of the CNAMTS, the FVE of the 2010/2011 seasonal trivalent vaccine against laboratory confirmed infection with any influenza virus was 59% (95% Confidence Interval, 17 to 81). It was 85% (17 to 99) and 50% (-16 to 80) for A(H1N1)pdm09 and B influenza infections, respectively. The values of FVE using the influenza VC obtained in a sample of the general population and of the population of GPs' patients were 73% (45 to 87) and 82% (63 to 92), respectively. We estimated a moderate influenza FVE in preventing confirmed influenza viruses in target groups by using the VC of the CNAMTS. We also observed that the screening method generates FVE values dependent on the choice of the source of VC and thus should be used cautiously.

Entities:  

Keywords:  general practitioners; influenza; target groups; vaccination coverage; vaccine effectiveness

Mesh:

Substances:

Year:  2013        PMID: 23811610      PMCID: PMC3981856          DOI: 10.4161/hv.25513

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  28 in total

1.  Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks.

Authors:  Marta Valenciano; Esther Kissling; Bruno Christian Ciancio; Alain Moren
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

2.  Real-time monitoring of the influenza vaccine field effectiveness.

Authors:  Judith Legrand; Elisabeta Vergu; Antoine Flahault
Journal:  Vaccine       Date:  2006-06-09       Impact factor: 3.641

3.  Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009.

Authors:  P Tuppin; S Samson; A Weill; P Ricordeau; H Allemand
Journal:  Vaccine       Date:  2011-05-06       Impact factor: 3.641

4.  Review of the 2010–2011 winter influenza season, northern hemisphere.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2011-05-27

5.  Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2010-03-05

6.  Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures.

Authors:  Joshua G Petrie; Suzanne E Ohmit; Emileigh Johnson; Rachel T Cross; Arnold S Monto
Journal:  J Infect Dis       Date:  2011-03-04       Impact factor: 5.226

7.  A new influenza surveillance system in France: the Ile-de-France "GROG". 1. Principles and methodology.

Authors:  C Hannoun; W Dab; J M Cohen
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

8.  Estimation of vaccine effectiveness using the screening method.

Authors:  C P Farrington
Journal:  Int J Epidemiol       Date:  1993-08       Impact factor: 7.196

9.  Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness.

Authors:  Evan W Orenstein; Gaston De Serres; Michael J Haber; David K Shay; Carolyn B Bridges; Paul Gargiullo; Walter A Orenstein
Journal:  Int J Epidemiol       Date:  2007-04-02       Impact factor: 7.196

10.  Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.

Authors:  Camille Pelat; Alessandra Falchi; Fabrice Carrat; Anne Mosnier; Isabelle Bonmarin; Clément Turbelin; Sophie Vaux; Sylvie van der Werf; Jean Marie Cohen; Bruno Lina; Thierry Blanchon; Thomas Hanslik
Journal:  PLoS One       Date:  2011-05-10       Impact factor: 3.240

View more
  4 in total

1.  Effectiveness of 2012-2013 influenza vaccine against influenza-like illness in general population: estimation in a French web-based cohort.

Authors:  Marion Debin; Vittoria Colizza; Thierry Blanchon; Thomas Hanslik; Clement Turbelin; Alessandra Falchi
Journal:  Hum Vaccin Immunother       Date:  2013-12-16       Impact factor: 3.452

2.  Early estimates of 2014/15 seasonal influenza vaccine effectiveness in preventing influenza-like illness in general practice using the screening method in France.

Authors:  Cécile Souty; Thierry Blanchon; Isabelle Bonmarin; Daniel Lévy-Bruhl; Sylvie Behillil; Vincent Enouf; Martine Valette; Maude Bouscambert; Clément Turbelin; Lisandru Capai; Victoire Roussel; Thomas Hanslik; Alessandra Falchi
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.

Authors:  Cornelius Remschmidt; Thorsten Rieck; Birte Bödeker; Ole Wichmann
Journal:  BMC Infect Dis       Date:  2015-03-20       Impact factor: 3.090

4.  New theoretical ISM-K2 Bayesian network model for evaluating vaccination effectiveness.

Authors:  Xiaoliang Xie; Bingqi Xie; Dan Xiong; Muzhou Hou; Jinxia Zuo; Guo Wei; Julien Chevallier
Journal:  J Ambient Intell Humaniz Comput       Date:  2022-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.